<qa>  What is the cross-over placebo controlled trial of edoxaban?The potential benefits of pharmacologic inhibition of FXa will be studied among HIV positive participants receiving ART with suppressed HIV viral load and a D-dimer 100 ngmL. The study design is a cross-over placebo controlled randomized trial of edoxaban 30mg daily versus matched placebo n40 total participants. After screening and baseline visits, participants will be randomized to the sequence of drug administration i.e., edoxaban vs. placebo. After randomization, participants will start study medication 1 and follow-up for visits at months 1, 2, 3 and 4. They will then stop study medication for 3 months, return for visits at months 7 and 8 analogous to screening and baseline, respectively, then start study medication 2 and follow-up for visits at months 9, 10, 11, and 12. 